Data from Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

Abstract

<div>Abstract<p>The molecular mechanisms leading to resistance to PD-1 blockade are largely unknown. Here, we characterize tumor biopsies from a patient with melanoma who displayed heterogeneous responses to anti–PD-1 therapy. We observe that a resistant tumor exhibited a loss-of-function mutation in the tumor suppressor gene <i>FBXW7</i>, whereas a sensitive tumor from the same patient did not. Consistent with a functional role in immunotherapy response, inactivation of <i>Fbxw7</i> in murine tumor cell lines caused resistance to anti–PD-1 in immunocompetent animals. Loss of <i>Fbxw7</i> was associated with altered immune microenvironment, decreased tumor-intrinsic expression of the double-stranded RNA (dsRNA) sensors MDA5 and RIG-I, and diminished induction of type I IFN and MHC-I expression. In contrast, restoration of dsRNA sensing in <i>Fbxw7</i>-deficient cells was sufficient to sensitize them to anti–PD-1. Our results thus establish a new role for the commonly inactivated tumor suppressor <i>FBXW7</i> in viral sensing and sensitivity to immunotherapy.</p>Significance:<p>Our findings establish a role of the commonly inactivated tumor suppressor <i>FBXW7</i> as a genomic driver of response to anti–PD-1 therapy. <i>Fbxw7</i> loss promotes resistance to anti–PD-1 through the downregulation of viral sensing pathways, suggesting that therapeutic reactivation of these pathways could improve clinical responses to checkpoint inhibitors in genomically defined cancer patient populations.</p><p><i>This article is highlighted in the In This Issue feature, p. 1241</i></p></div>